206 related articles for article (PubMed ID: 37163340)
1. Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics.
Wang J; Zhang J; Wang J; Hu X; Ouyang L; Wang Y
J Med Chem; 2023 May; 66(10):6437-6462. PubMed ID: 37163340
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Modulators of Toll-like Receptors.
Wang Y; Zhang S; Li H; Wang H; Zhang T; Hutchinson MR; Yin H; Wang X
Acc Chem Res; 2020 May; 53(5):1046-1055. PubMed ID: 32233400
[TBL] [Abstract][Full Text] [Related]
3. Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity.
Huang CH; Mendez N; Echeagaray OH; Weeks J; Wang J; Vallez CN; Gude N; Trogler WC; Carson DA; Hayashi T; Kummel AC
ACS Appl Mater Interfaces; 2019 Jul; 11(30):26637-26647. PubMed ID: 31276378
[TBL] [Abstract][Full Text] [Related]
4. Clinical investigations of Toll-like receptor agonists.
Meyer T; Stockfleth E
Expert Opin Investig Drugs; 2008 Jul; 17(7):1051-65. PubMed ID: 18549341
[TBL] [Abstract][Full Text] [Related]
5. Targeting Toll-like receptors with small molecule agents.
Wang X; Smith C; Yin H
Chem Soc Rev; 2013 Jun; 42(12):4859-66. PubMed ID: 23503527
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy.
Yang Y; Feng R; Wang YZ; Sun HW; Zou QM; Li HB
Immunol Lett; 2020 Jul; 223():1-9. PubMed ID: 32311408
[TBL] [Abstract][Full Text] [Related]
8. Drugs targeting Toll-like receptors.
Krishnan J; Lee G; Choi S
Arch Pharm Res; 2009 Nov; 32(11):1485-502. PubMed ID: 20091261
[TBL] [Abstract][Full Text] [Related]
9. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
10. Immune response modifiers--mode of action.
Schiller M; Metze D; Luger TA; Grabbe S; Gunzer M
Exp Dermatol; 2006 May; 15(5):331-41. PubMed ID: 16630072
[TBL] [Abstract][Full Text] [Related]
11. Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases.
Wicherska-Pawłowska K; Wróbel T; Rybka J
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948194
[TBL] [Abstract][Full Text] [Related]
12. TLR activation pathways in HIV-1-exposed seronegative individuals.
Biasin M; Piacentini L; Lo Caputo S; Naddeo V; Pierotti P; Borelli M; Trabattoni D; Mazzotta F; Shearer GM; Clerici M
J Immunol; 2010 Mar; 184(5):2710-7. PubMed ID: 20124101
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives.
Mukherjee S; Patra R; Behzadi P; Masotti A; Paolini A; Sarshar M
Front Immunol; 2023; 14():1244345. PubMed ID: 37822929
[TBL] [Abstract][Full Text] [Related]
14. Application potential of toll-like receptors in cancer immunotherapy: Systematic review.
Shi M; Chen X; Ye K; Yao Y; Li Y
Medicine (Baltimore); 2016 Jun; 95(25):e3951. PubMed ID: 27336891
[TBL] [Abstract][Full Text] [Related]
15. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.
Engel AL; Holt GE; Lu H
Expert Rev Clin Pharmacol; 2011 Mar; 4(2):275-89. PubMed ID: 21643519
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptors and their role in hematologic malignancies.
Wolska A; Lech-Maranda E; Robak T
Curr Mol Med; 2009 Apr; 9(3):324-35. PubMed ID: 19355914
[TBL] [Abstract][Full Text] [Related]
17. Interferon and Toll-Like Receptor 7 Response in COVID-19: Implications of Topical Imiquimod for Prophylaxis and Treatment.
Szeto MD; Maghfour J; Sivesind TE; Anderson J; Olayinka JT; Mamo A; Runion TM; Dellavalle RP
Dermatology; 2021; 237(6):847-856. PubMed ID: 34511591
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action and other potential roles of an immune response modifier.
Gaspari AA
Cutis; 2007 Apr; 79(4 Suppl):36-45. PubMed ID: 17508494
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors in breast cancer immunity and immunotherapy.
Zhou J; Zhang L; Liu S; DeRubeis D; Zhang D
Front Immunol; 2024; 15():1418025. PubMed ID: 38903515
[TBL] [Abstract][Full Text] [Related]
20. Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.
Kirtland ME; Tsitoura DC; Durham SR; Shamji MH
Front Immunol; 2020; 11():599083. PubMed ID: 33281825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
